These findings support the continued development of GRPR-targeted peptide therapeutics and provide a strong rationale for advancing BU peptide toward in vivo evaluation and clinical translation for the treatment of refractory and hypoxic SCLC. The gene discussed is GRPR; the disease is small cell lung carcinoma.